Developmental excitation-inhibition imbalance underlying psychoses revealed by single-cell analyses of discordant twins-derived cerebral organoids

Tomoyo Sawada 1,2,3 • Thomas E. Chater 4 • Yohei Sasagawa 5 • Mika Yoshimura 5 • Noriko Fujimori-Tonou 1 • Kaori Tanaka 5 • Kynon J. M. Benjamin 2,3 • Apuã C. M. Paquola 2,3 • Jennifer A. Erwin 2,3,6 • Yukiko Goda 4 • Itoshi Nikaido 5,7,8 • Tadafumi Kato 1,9

Received: 17 January 2020 / Revised: 23 June 2020 / Accepted: 10 July 2020 / Published online: 7 August 2020
© The Author(s) 2020. This article is published with open access

Abstract
Despite extensive genetic and neuroimaging studies, detailed cellular mechanisms underlying schizophrenia and bipolar disorder remain poorly understood. Recent progress in single-cell RNA sequencing (scRNA-seq) technologies enables identification of cell-type-specific pathophysiology. However, its application to psychiatric disorders is challenging because of methodological difficulties in analyzing human brains and the confounds due to a lifetime of illness. Brain organoids derived from induced pluripotent stem cells (iPSCs) of the patients are a powerful avenue to investigate the pathophysiological processes. Here, we generated iPSC-derived cerebral organoids from monozygotic twins discordant for psychosis. scRNA-seq analysis of the organoids revealed enhanced GABAergic specification and reduced cell proliferation following diminished Wnt signaling in the patient, which was confirmed in iPSC-derived forebrain neuronal cells. Two additional monozygotic twin pairs discordant for schizophrenia also confirmed the excess GABAergic specification of the patients’ neural progenitor cells. With a well-controlled genetic background, our data suggest that unbalanced specification of excitatory and inhibitory neurons during cortical development underlies psychoses.

Introduction
Schizophrenia (SZ) and bipolar disorder (BD) are among the most intractable disorders in brain health. Both illnesses share complex genetic/environmental etiologies, molecular neuropathology, neurodevelopmental origin, and a subset set of symptoms including psychosis. Genetic and neuroimaging studies have shown clues to understand biological bases of these psychiatric disorders. However, responsible
cell types for the pathogenesis and consequences of their dysfunction have not been fully elucidated because of methodological limitations on cellular complexity of the brain.

Recent development and progress of single-cell RNA sequencing (scRNA-seq) technologies enabled the identification of cell-type-specific pathological processes. Although scRNA-seq has been applied to human post-mortem brains [1–3], confounding factors and methodological difficulties hampered the application of this technology to identification of cellular alterations underlying psychiatric disorders with patients’ postmortem brains.

Brain organoids have become an important experimental tool to investigate structural and functional complexity of human brain development and neurodevelopmental disorders [4–7]. Taking neurodevelopmental origins into account, brain organoids derived from induced pluripotent stem cells (iPSCs) of the patients are an optimal tool to identify the cell-type-specific pathophysiology of SZ and BD.

Mounting research using patient-derived iPSCs has proposed several cellular pathways altered in these psychiatric disorders, including synaptic function and Wnt signaling [8]. However, most of these studies differentiated the iPSCs into a predefined specific cell type. Therefore, the developmental trajectory that leads to altered brain development in these disorders remains unknown. Moreover, sporadic case-control designs used in the previous studies have large heterogeneous genotypic differences. Due to substantial heterogeneity, the specificity of and relationships among these pathways in neuropsychiatric disorders and the developmental trajectory that leads to altered brain construction remain unclear. Thus, simulating brain development with a well-controlled genetic background [9] is also essential for progress in this field.

Here, we applied Quartz-Seq2 [10], which showed outstanding performance among scRNA-seq methods by benchmarking [11], to iPSC-derived cerebral organoid models of psychosis. To detect disease-specific alterations minimizing inter-individual genetic variations, we analyzed the organoids of a pair of monozygotic twins discordant for psychoses and verified the findings in two additional monozygotic twins discordant for SZ.

Materials and methods

Participants

A Japanese family including a pair of male monozygotic twins discordant for schizoaffective disorder, bipolar type (DT1_A, DT1_U, C1, and C2) (Figs. 1a and S1A) and two pairs of monozygotic twins discordant for SZ (DT2_A and DT2_U [12] and DT3_A and DT3_U [13] (Fig. S1A) were included in this study. Array-based comparative genome hybridization (array CGH) analysis confirmed monozygosity of DT1 (Fig. S1B). All twins had been discordant for the disease for at least 3 years prior to the day of blood sampling. Two of healthy male control individuals (C3 and C4) (Fig. S1A) were also enrolled. All participants were screened for mental disorders by trained psychiatrists using the Mini International Neuropsychiatric Interview [14]. Detailed information regarding participant characteristics is presented in Fig. S1A. Written informed consent was obtained from all participants, and all experiments involving human iPSCs were approved by the Wako 1st Research Ethics Committee of RIKEN (Wako 1: 15-4(41)).

Derivation, cultivation, and characterization of human iPSCs

For DT1_A, DT1_U, C1, C2, C3, and C4, iPSCs were established from peripheral blood mononuclear cells (PBMCs). PBMCs were purified via density gradient centrifugation with Ficoll-Paque PREMIUM (GE Healthcare, IL, USA), in accordance with the manufacturer’s instructions. We generated iPSCs using episomal vectors, as previously described [15, 16]. Briefly, plasmids pCXLE-hOCT3/4-shp53-F, pCXLE-hSK, pCXLE-hUL, and pCXWB-EBNA1 (Addgene, MA, USA) were transfected into PBMCs using Nucleofector II (Lonza, Basel, Switzerland; program V-024) at a concentration of 3 μg per 100 μl solution per 3 × 10⁶ cells, and an Amaxa Human T Cell Nucleofector kit (Lonza). The transfected cells were then seeded onto 100-mm dishes covered with mitomycin C-treated SNL76/7 feeder cells (ATCC, VA, USA) in KBMS02 (Kohjin Bio, Saitama, Japan) supplemented with 16.7 μl/10⁸ cells of Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher Scientific, MA, USA). Two days after transfection, an equal volume of iPSC medium consisting of DMEM/F12 + GlutaMAX, 20% Knockout Serum Replacement (KSR), 1 × MEM NEAA, 100 μM 2-methylscopeltoethanol, 0.5 × penicillin/streptomycin (Thermo Fisher Scientific), and 4 ng/ml human basic FGF (bFGF) (Wako, Osaka, Japan) was added. The culture medium was then replaced with iPSC medium every other day until iPSC colonies appeared. For DT2_A, DT2_U, DT3_A, and DT3_U, iPSCs were generated from lymphoblastoid cell lines (LCLs). LCLs were maintained in LCL medium consisting of RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS and 0.5 × penicillin/streptomycin. In accordance with previously described methods [17], cells were reprogrammed by electroportating 2 × 10⁶ cells with 1 μg each of pCXLE-hOCT3/4-shp53-F, pCXLE-hSK, and pCXLE-hUL using a Neon transfection system (Thermo Fisher Scientific). Transfection parameters...
were as follows: 1100 V, 30 ms, two pulses. Transfected cells were cultivated in the LCL medium for 24 h, following which half of the medium was replaced with iPSC medium and were further incubated for 24 h. Forty-eight hours after electroporation, the cells were seeded onto SNL feeder cells and maintained in iPSC medium. Three to five weeks later, iPSC colonies were manually picked up for further expansion and characterization. The iPSCs were maintained on feeder cells in iPSC medium and passaged every 4–6 days with CTK solution consisting of 0.25% trypsin, 0.1 mg/ml Collagenase Type IV, 1 mM CaCl₂, and 20% KSR as previously described [18].

To evaluate a neural differentiation potency of established iPSCs, we differentiated them (eight clones each from DT1_A and DT1_U) into neural progenitor cells (NPCs) via the serum-free floating culture of embryoid body-like aggregates with quick reaggregation (SFEBq) method, as previously described [19] (Fig. S1C). Briefly, iPSCs treated overnight with 10 μM Y-27632 (Wako) were dissociated into single cells using Accumax (Innovative Cell Technologies, CA, USA) and transferred to Prime-Surface 96U plates (Sumitomo bakelite, Tokyo, Japan) at a density of 9000 cells/well. The cells were cultured for 14 days in DFK5 medium consisting of DMEM/F12 + GlutaMAX, 5% KSR, 1 × MEM NEAA, 100 μM 2-ME, and 0.5 × penicillin/streptomycin. The medium was supplemented with 30 μM Y-27632, 10 μM SB431542 (Sigma, MO, USA), and 100 nM LDN-193189 (Miltenyi Biotec, Bergisch Gladbach, Germany) for the first 4 days. Neural aggregates on day 14 were dissociated into single cells using Accutase (Innovative Cell Technologies) and stained with anti-PSA-NCAM-PE (Miltenyi Biotec) and anti-TRA-1-60-FITC (BD Biosciences, NJ, USA) antibodies, in accordance with the manufacturer’s protocols. The cells were then stained with 7-AAD (BD Biosciences) to exclude dead cells and analyzed using FACS Aria II (BD Biosciences). Unstained cells were used as a negative control. Data were analyzed using FlowJo software (BD Biosciences). Expression of pluripotent stem cell markers was examined by quantitative RT-PCR (RT-qPCR) and RT-PCR with primers listed on Table S1 and immunofluorescent staining with antibodies against OCT4, TRA-1-60, and TRA-1-81 (see details in Table S2). The pluripotency of established iPSC lines was validated by karyotyping analysis of the iPSCs. Karyotyping analysis of the iPSCs was conducted via G-banding (Chromocenter Inc., Tottori, Japan).

Cell culture

SNL76/7 feeder cells were maintained in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS and 0.5 × penicillin/streptomycin on 0.1% gelatin-coated plates. To inhibit proliferation, we treated the SNL76/7 cells with 12.4 μg/ml Mitomycin C (Sigma) for 2.25 h. The human iPSC line 409B2 was provided by the RIKEN BRC (Ibaraki, Japan) through the Project for Realization of Regenerative Medicine and the National Bio-Resource Project of the MEXT, Japan [15]. Human dermal fibroblasts (HDFs) (RIKEN BRC) were maintained in MEM α (Thermo Fisher Scientific) supplemented with 10% FBS. To quantify the exogenous expression of reprogramming factors, HDFs were transfected with the episomal vectors using Neon at a concentration of 3 μg per 3 × 10⁵ cells. Transfection parameters were as follows: 1650 V, 10 ms, three pulses. Four days after electroporation, the cells were harvested and subjected to further analyses. For RT-PCR, PBMCs were expanded in KBM502 on 100-mm dishes coated with anti-Human CD3 antibodies (BD Biosciences) to activate the proliferation of T cells.

Genomic DNA extraction

Genomic DNA was extracted from peripheral blood samples using a genomic DNA Extraction kit (GenomiX, Trieste, Italy). Genomic DNA of cultured cells was extracted using a DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany). The concentration of extracted dsDNA was measured using a Qubit 2.0 Fluorometer and a Qubit dsDNA HS Assay kit (Thermo Fisher Scientific).

RNA extraction and (q)PCR

Total cellular RNA was extracted from iPSCs or neuronal cells using TRizol Reagent (Thermo Fisher Scientific) and a Direct-zol RNA MiniPrep kit (Zymo Research, CA, USA), in accordance with the manufacturer’s instructions. Reverse transcription was performed with the oligo dT20 primer using a RverTra Ace-α-kit (Toyobo, Osaka, Japan). RT-PCR was carried out with Ex Taq HS on Veriti 96-Well Thermal Cycler (Thermo Fisher Scientific). RT-qPCR was performed using SYBR Premix Ex Taq II (Takara Bio) on QuantStudio 12 K Flex Real-Time PCR System (Thermo Fisher Scientific). The primer sequences are shown in Table S1.
Array-based comparative genome hybridization (array CGH) analysis

Array CGH was performed using a SurePrint G3 Human CGH Microarray kit, 1 × 1 M (Agilent Technologies, CA, USA). Labeling was performed using a SureTag Complete DNA Labeling kit (Agilent Technologies). Microarray slides were scanned using an Agilent microarray scanner, and scanned images were digitized using Feature Extraction Software. The data were then analyzed using GeneSpring GX (Agilent Technologies).

Generation and culture of cerebral organoids

Cerebral organoids were generated as previously described, with modifications [20]. Briefly, after removal of SNL feeders from iPSC cultures with CTK solution, iPSCs were dissociated into single cells using Accumax and transferred to PrimeSurface 96U plates at a density of 9000 cells/well. The cells were cultured for 8 days in DFK5 medium supplemented with 10 μM SB431542 and 100 nM LDN-193189. The medium was also supplemented with 30 μM Y-27632 for the first 4 days. On day 8, EBs were transferred to Ultra Low Attachment 24-well plates (Corning) in neural induction medium (NIM) consisting of DMEM/F12 + GlutaMAX, 1 × N2 Supplement (Thermo Fisher Scientific), 1 × MEM NEAA, 1 μg/ml Heparin (Sigma), 0.5 × penicillin/streptomycin, and 100 nM LDN-193189. An equal volume of NIM was added 48 h after transferring them to 24-well plates. On day 12, each EB was embedded in a Matrigel Basement Membrane Matrix Growth Factor Reduced (GFR) (Corning) droplet and transferred to a 60-mm culture dish in neural differentiation medium minus (NDM−) consisting of a 1:1 mixture of DMEM/F12 and Neurobasal medium (Thermo Fisher Scientific) supplemented with 0.5 × N2 Supplement, 0.5 × B27 Supplement minus Vitamin A (Thermo Fisher Scientific), 0.5 × MEM NEAA, 1 × GlutaMAX, 100 μM 2-ME, and 2.65 μg/ml Insulin without agitation. The medium was replaced on day 14. After 4 days in static culture, the medium was changed to neural differentiation medium plus (NDM+) in which B27 Supplement minus Vitamin A was replaced with B27 Supplement (with Vitamin A). The culture was then agitated on an orbital shaker (IKA, Staufen, Germany) at 80 r.p.m. The medium was replaced every 3–4 days. For rescue experiments, the EBs/organoids were treated with 1 mM LiCl (Sigma) or 100 ng/ml Wnt3a (R&D systems, MN, USA) for 8 days (days 4–12). On days 30 and 35, the organoids were fixed and immunostained with appropriate antibodies, and subjected to scRNA-seq analysis, respectively. The size of the SOX2+ ventricular zone (VZ)-like layer was measured using ImageJ software [21]. The quantification was performed in an unblinded manner. The ambiguous boundary between SOX2+ and SOX2− cells was determined based on the expression of DCX, which was contained with SOX2 on the serial sections. The Fluorescence intensity of GABA on the cerebral organoid slices were measured with ImageJ software. Threshold was determined by Yen’s methods. Total fluorescence intensity was divided by the area.

Quartz-Seq2 single-cell RNA-seq analysis

On day 35, cerebral organoids from DT1_A and DT1_U (two organoids for each iPSC clone) were incubated in cell recovery solution (Corning) on ice for 45 min. After washing twice with PBS, the organoids were incubated in Accutase at 37 °C for 20 min and then dissociated into single cells by pipetting up and down. Cells were rinsed with FACS buffer consisting of HBSS (Thermo Fisher Scientific) supplemented with 0.5% BSA (MP Biomedicals, CA, USA) and filtered through a 35-μm nylon mesh (BD Biosciences). After centrifugation, cells were resuspended in FACS buffer and stained with 7-AAD at room temperature for 15 min. Each living single cell was then sorted into lysis buffer in a 384-well PCR plate (Eppendorf, Hamburg, Germany) at 4 °C using FACS Aria II. Sequence library DNA was prepared in accordance with methods described in our previous study [10]. The libraries were analyzed using NextSeq 500/550 High Output v2 kit (75 cycles) with NextSeq 500 sequencer (Illumina, CA, USA). The sequence specification of Quartz-Seq2 was as follows: Read1, 22 cycles; index1, 6 cycles; and Read2, 64 cycles. Bcl files were converted to fastq files using bcl2fastq2 (v2.17.1.14) (Illumina). We then processed fastq files into a digital expression matrix, as in our previous study [10]. During this process, we trimmed read2 length to 63 nucleotides using the FASTXT-Toolkit (version 0.0.14) (https://github.com/agordon/fastx_toolkit/blob/master/reconf). The versions of databases for the process were as follows: human genome, GRCh38.primary_assembly.genome.fa; genome annotation, gencode.v27.primary_assembly.annotation.gtf; and Drop-seq tools, v1.11 [22]. The average number of fastq reads per well was ~95,000. We detected ~4800 gene counts and 20,000 unique molecular identifier counts per well on average. The copy number of ERCC spike-in RNA at 50% detection probability for Quartz-Seq2 was ~2.18 (Table S3).

Highly variable genes across a population of cells were selected for secondary analysis using DESeq2 1.16.1 [23] and statmod 1.4.30 R package [24]. First, we selected genes with CV2 values higher than 0.3, following which we calculated the 95th percentile. We then removed genes with median values below the 95th percentile, and the average
expression in each gene and log-transformed CV2 were fitted using the glmgam.fit function. Finally, we evaluated the statistical significance of the deviation from the fitting curve for each gene using chi-square tests, setting the p-value parameter to 0.001 (final set: 7469 genes). Abnormal cell clusters with a proportion of mitochondrial gene expression higher than 12% or fewer than 10–3000 expressed genes were excluded using the kmeans function in stats R package (https://stat.ethz.ch/R-manual/R-devel/library/stats/html/00Index.html), setting the k parameter to 7 (final set: 2782 cells). The digital gene expression matrix was added to 1 and log-transformed. Dimensional reduction of cells derived from all organoids was performed using the Rtsne 0.13 function [25], setting the perplexity to 40. Cell typing was performed using kmeans based on the expression profile of cell-type-specific markers (Table S4) [26–29]. DEGs between affected and unaffected samples in each cell type were calculated using the glmlR function in edgeR 3.18.1 R package [30]. Pathway enrichment analysis of DEGs was performed using IPA software (Qiagen). For visualization of gene expression data, ggplot2 2.2.1 [31], pheatmap 1.0.10 (https://cran.r-project.org/web/packages/pheatmap/index.html), and Rtsne 0.13 were used.

**Differentiation of iPSCs into forebrain-specific neural stem/progenitor cells (NSPCs) and cortical neurons**

We differentiated iPSCs into forebrain-specific NSPCs according to a previous report [32] with slight modifications. On day 8 of cerebral organoid differentiation, EBs were transferred onto 6-well culture plates (Corning) coated with Matrigel GFR at a density of 48 EBs/well in DFN2 medium consisting of DMEM/F12 with 100 μM EdU for 3 or 24 h. Thereafter, cells were dissociated into single cells using Accutase and stained with anti-CD15-APC antibody (BD Biosciences), in accordance with the manufacturer’s instructions. Then, the cells were prepared for detection using a Click-iT Plus EdU Flow Cytometry Assay kit (Thermo Fisher Scientific), in accordance with the manufacturer’s protocol. DNA was stained with 1 μg/ml DAPI (BD Biosciences). The cells were analyzed using FACS Aria II. Unstained cells were used as a negative control. Data were analyzed using FlowJo software. For 30-day-old NSPCs, cells were labeled with 10 μM EdU for 3 h, and signal detection was performed using a Click-iT EdU Imaging kit (Thermo Fisher Scientific), according to the manufacturer’s protocol. After detecting EdU, cells were further immunostained with anti-Nestin antibody (MBL, Aichi, Japan). The proportion of EdU+/Nestin+ cells was measured using the ImageJ Cell Counter plugin.

**EdU incorporation assay**

To measure the proliferative activity of NSPCs, EdU incorporation assays were performed in 8-day-old EBs and 30-day-old NSPCs. For EB samples, cells were incubated with 10 μM EdU for 3 or 24 h. Thereafter, cells were dissociated into single cells using Accutase and stained with anti-CD15-APC antibody (BD Biosciences), in accordance with the manufacturer’s instructions. Then, the cells were prepared for detection using a Click-iT Plus EdU Flow Cytometry Assay kit (Thermo Fisher Scientific), in accordance with the manufacturer’s protocol. DNA was stained with 1 μg/ml DAPI (BD Biosciences). The cells were analyzed using FACS Aria II. Unstained cells were used as a negative control. Data were analyzed using FlowJo software. For 30-day-old NSPCs, cells were labeled with 10 μM EdU for 3 h, and signal detection was performed using a Click-iT EdU Imaging kit (Thermo Fisher Scientific), according to the manufacturer’s protocol. After detecting EdU, cells were further immunostained with anti-Nestin antibody (MBL, Aichi, Japan). The proportion of EdU+/Nestin+ cells was measured using the ImageJ Cell Counter plugin.

**Electrophysiological analysis**

Whole-cell patch-clamp recordings were obtained from iPSC-derived cortical neurons placed on the stage of an Axio Examiner upright microscope (Carl Zeiss, Oberkochen, Germany) using a Multiclamp amplifier (Molecular Devices, CA, USA). The recording chamber was continuously perfused with an extracellular solution containing 130 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1.5 mM MgCl2, 10 mM D-glucose, and 10 mM HEPES (pH 7.35, osmolarity adjusted to 290 mOsm). For miniature IPSCs, 1 μM TTX (Tocris Bioscience, Bristol, UK) was added to the recording solution. For miniature EPSCs, 1 μM TTX and 50 μM picrotoxin (Sigma) were added to the recording solution. Micropipettes were made from borosilicate glass capillaries, with a resistance in the range of 3–6 MΩ. The intracellular solution contained 100 mM K-gluconate, 17 mM KCl, 5 mM NaCl, 5 mM MgCl2, 10 mM HEPES, 0.5 mM EGTA, 4 mM ATPK2, and 0.5 mM GTPNa (pH 7.3, osmolarity adjusted to 280 mOsm). All recordings were performed at room temperature (21–24 °C). Events were recorded at 10 kHz and analyzed offline. All analyses were performed using Clampfit software (Molecular Devices).

**Morphological analysis of iPSC-derived neurons**

To assess the morphology of iPSC-derived cortical neurons, cells were transfected with a plasmid coding for EGFP (pEGFP-N1) (Clontech, CA, USA) using Lipofectamine...
DEGs were performed using IPA software. Calculated mean insert size for all samples. Pathway analyses of using picard tools utility:

```bash
$FASTA -o $OUTPUT $BAM
calculator
```

treatmentCounts -p -s 2 -Q 60 -B -C --primary -a $GTF -G

excluded chimeric reads, and (4) primary alignment of Illumina. The length of libraries was 316 bp, including adapter sequences. Samples were sequenced paired end 2 × 101 bp on a HiSeq 2500 system (Illumina). For data processing, we aligned reads to the GRCh38 human genome (GENCODE release 26, GRCh38.p10) using HISAT2 (v2.1.0) [33]. We generated gene counts using the SubRead utility featureCounts (v1.5.3) [34] for paired end, reversed stranded read counting using read-level filters including: (1) uniquely mapped reads corresponding to a mapping quality of 60 for Hisat2 BAM files, (2) reads aligned in proper pairs, (3) excluded chimeric reads, and (4) primary alignment (=featureCounts -p -s 2 -Q 60 -B -C --primary -a SGTF -G SFASTA -o SOUTPUT SBAM = ). Gene counts were converted to TPM using effective read lengths determined by using picard tools utility =CollectInsertSizeMetrics= to calculated mean insert size for all samples. Pathway analyses of DEGs were performed using IPA software.

### Bulk RNA-seq analysis

NSPCs on day 8 and 24 were used for gene expression analyses. Total RNA was isolated using the TRIzol reagent and a PureLink RNA Micro kit (Thermo Fisher Scientific) or Direct-zol RNA MiniPrep kit (Zymo Research). RNA-seq libraries were prepared from the purified RNA using a TruSeq RNA Sample Preparation kit v2 (Illumina). The length of libraries was 316–429 bp, including adapter sequences. Samples were sequenced paired end 2 × 101 bp on a HiSeq 2500 system (Illumina). For data processing, we aligned reads to the GRCh38 human genome (GENCODE release 26, GRCh38.p10) using HISAT2 (v2.1.0) [33]. We generated gene counts using the SubRead utility featureCounts (v1.5.3) [34] for paired end, reversed stranded read counting using read-level filters including: (1) uniquely mapped reads corresponding to a mapping quality of 60 for Hisat2 BAM files, (2) reads aligned in proper pairs, (3) excluded chimeric reads, and (4) primary alignment (=featureCounts -p -s 2 -Q 60 -B -C --primary -a SGTF -G SFASTA -o SOUTPUT SBAM = ). Gene counts were converted to TPM using effective read lengths determined by using picard tools utility =CollectInsertSizeMetrics= to calculated mean insert size for all samples. Pathway analyses of DEGs were performed using IPA software.

### Immunocytochemistry

Cells were fixed with 4% PFA in PBS for 10 min at room temperature and then permeabilized with 0.2% Triton X-100 in PBS for 15 min at room temperature. Cells were then blocked with 10% normal donkey serum in PBS containing 0.01% Tween-20 for 30 min at room temperature or overnight at 4°C. After blocking, cells were incubated with primary antibodies diluted in blocking solution at 4°C overnight, followed which they were incubated with secondary antibodies for 2 h at room temperature. Cells were finally incubated with 1 μg/ml Hoechst 33342 (Thermo Fisher Scientific) for 10 min at room temperature. Fluorescent signals were detected using a Zeiss AxiosObserver.Z1 Microscope with ApoTome.2 (Carl Zeiss), and images were processed using ZEN software (Carl Zeiss) and Photoshop CS6 software (Adobe, CA, USA). The numbers of excitatory and inhibitory synaptic puncta were manually counted. The size of gephyrin puncta was analyzed using the ImageJ Analyze particles plugin. The proportion of GABAergic neurons was measured using the ImageJ Cell Counter plugin.

For immunostaining of cerebral organoids, the organoids were fixed with 4% PFA in PBS overnight at 4°C on day 30. After washing with PBS, organoids were placed in serial dilutions of PBS-buffered sucrose (10, 20, and 30%, in sequence) at 4°C. Each solution was replaced every day. The dehydrated organoids were maintained in 30% sucrose solution at 4°C until embedding with OCT compound (Sakura Finetek, Tokyo, Japan). One day before cryosectioning, organoids were placed in a 1:2 mixture of 30% sucrose solution and OCT compound and left overnight at 4°C. Then, organoids were embedded in a 1:2 mixture of 30% sucrose solution and OCT compound and frozen immediately in dry ice/acetone. Cryosections (10 μm) were subjected to additional fixation with 4% PFA in PBS for 3 min at room temperature, following which they were permeabilized and blocked with 10% normal donkey serum in PBS containing 0.3% Triton X-100 for 30 min at room temperature. After washing with 5% serum in PBS containing 0.01% Tween-20, sections were incubated with primary and secondary antibodies. Detailed information regarding antibodies is available on Table S2.

### Analysis of postmortem brain gene expression data

We downloaded BrainSeq Consortium, dorsolateral prefrontal cortex FASTQ files [35]. The reads were aligned as previously described [35, 36] with slight modification. Briefly, we generated TPM estimates by aligning the reads to the GRCh38 human genome (GENCODE release 26, GRCh38.p10) using Kallisto (v0.43.1) [37] and the reference transcriptome. The expression levels of transcripts encoding 146 genes annotated with GABAergic synapse and/or GABA receptor signaling were compared between the patients with SZ or schizoaffective disorder (“Schizo”) and non-psychiatric control individuals. Among multiple transcripts for each gene, we extracted one protein-coding transcript exhibited the highest expression in control samples.

### Statistical analysis

Statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software, CA, USA) and SPSS software (IBM, NY, USA). Two- or one-tailed Student’s or Welch’s t
tests were used for comparisons between two groups, while one-way ANOVA followed by Tukey’s multiple comparison tests were used for comparisons among three groups. To evaluate the effect of lithium chloride (LiCl) treatment, we performed three-way ANOVA. We also performed two-way ANOVA with post hoc Student’s or Welch’s t tests to evaluate the effect of lithium chloride (LiCl) treatment, we used to predetermine the sample size. The sample sizes and the numbers of trials are indicated in Table S5. Detailed statistical information can be found in the figure legends and is shown in Table S6. The sample sizes and the number of trials are indicated in Table S7. Each graph was drawn using ggplot2 library [31] in R studio [38].

Results

Affected twin-derived cerebral organoids show accelerated neuronal differentiation and enhanced GABAergic specification

We first established iPSCs from a pair of male monozygotic twins (DT1) discordant for schizoaffective disorder, bipolar type (SA-B), which shares clinical features including psychosis with both SZ and BD (Figs. 1a and S1A, B). First, we screened the neuronal differentiation potency of the iPSCs from the twins (Fig. S1C–F) and validated the quality of multiple selected clones from each individual (affected twin: DT1_A1, 2, 3, 4 and unaffected twin: DT1_U1, 2, 3, 4) for further functional analyses (Fig. S1G–M). To investigate the neurodevelopmental alterations underlying psychosis, we differentiated iPSCs into cerebral organoids (Fig. 1b) [6, 20]. On day 35, we performed scRNA-seq analysis with the Quartz-Seq2 method (Fig. 1c) [10]. We first classified each cell into neuronal and non-neuronal populations based on patterns of marker gene expression (Figs. 1d, S2A, S2D, and S4A). The neuronal population consisted of postmitotic cells expressing markers such as MAPT or STMN2, and proliferative progenitors were positive for markers such as SOX2 or NES (Fig. 1d and Table S4). The non-neuronal population included progenitors for astroglia, oligodendrocytes, mesenchymal cells, and the choroid plexus (Table S4). The cerebral organoid from the psychotic twin (DT1_A) had significantly fewer proliferative progenitors and remarkably more postmitotic cells than the healthy co-twin (DT1_U)-derived organoids (Figs. 1e, f and S3E, F), implying an accelerated commitment to neuronal differentiation in the affected twin. Moreover, DT1_A organoids tended to have fewer cycling cells, expressing markers such as HMGB2 or MKI67 (Fig. 1d and Table S4), than DT1_U organoids among the proliferative progenitor population (Figs. 1e, g and S3E, G). We then further deconstructed neuronal cell composition according to gene expression patterns (Figs. 1h, S2 and S4A–E, and Table S4). The postmitotic neuronal population contained glutamatergic, GABAergic and dopaminergic neurons (Figs. 1h and S4A–C). Among the progenitor population, cells were classified into three clusters consisting of dorsal progenitors, ventral progenitors, and midbrain progenitor + neuroectodermal cells (Figs. 1h and S4D, E). The proportions of glutamatergic or dopaminergic neurons among postmitotic cells were markedly lower in DT1_A than in DT1_U. In contrast, DT1_A organoids contained significantly more GABAergic neurons than DT1_U organoids (Figs. 1i, j and S4F, G). Although there was no significant difference in the ventricular progenitor proportion, DT1_A organoids included notably more ventral progenitors than DT1_U organoids. Alternatively, remarkably fewer midbrain progenitor + neuroectodermal cells were found in DT1_A organoids than in DT1_U organoids (Figs. 1i, k and S4F, H).

We next analyzed differentially expressed genes (DEGs) between the twins (Table S8). Compared with the gene expression in DT1_U organoids, 350 genes were down-regulated, and 219 genes were up-regulated in DT1_A organoids. IPA of those DEGs revealed significant down-regulation of cell cycle controlling pathways and Wnt signaling pathways in DT1_A. Conversely, “GABA Receptor Signaling” was clearly enriched among the upregulated genes in the affected twin. Moreover, there was a significant upregulation of genes regulating axon guidance in DT1_A organoids (Table S9).

Activation of the Wnt signaling pathway restores the deficit in cell proliferation and the excess GABAergic specification in the affected twin-derived cerebral organoids

To confirm the difference in the cellular composition during corticogenesis between the twins, we performed immunocytochemical analyses of the organoids. On day 30, cerebral organoids displayed a layered structure consisting of a SOX2+ VZ-like layer representing proliferative neural NPCs and a DCX+ neuronal layer (Fig. S5A, B). Consistent with the reduced proliferative progenitor population identified in scRNA-seq analysis, DT1_A organoids exhibited significantly smaller SOX2+ structures than DT1_U-derived organoids (Figs. 2a, b and S5C–E). In addition, we confirmed the increased GABAergic population in DT1_A organoids compared with that in DT1_U organoids (Figs. 2c, d and S6A, B). To explore the contribution of the diminished Wnt signaling pathway to these events, we
activated the pathway by treating the cells with LiCl, a GSK3β inhibitor, or Wnt3a. Interestingly, activation of Wnt/β-catenin signaling during the early neurodevelopmental stage clearly restored both the size of the SOX2+ layer and GABAergic neuronal proportion, especially in DT1_A organoids (Figs. 2a–d, S5D, E and S6A, B), suggesting that the decreased Wnt/β-catenin signaling activity affects the cell proliferation and fate specification in the developing brain of a psychotic patient. We confirmed the effect of variability among each iPSC clone on these findings was smaller than the effects of disease status or LiCl treatment (Figs. S5E and S6B and Table S6).

**Diminished Wnt signaling precedes the reduced NPC proliferation and the altered cell fate specification during early neurodevelopmental stages in the affected twin**

We next identified the order of cellular and molecular alterations observed in the affected twin-derived organoids...
by time-point profiling with monolayer neuronal cells. The iPSCs of the twins were differentiated into forebrain neural stem/progenitor cells (NSPCs) via the SFEBq method combined with dual SMAD inhibition (Fig. 3a) [32]. We first performed bulk RNA-seq of iPSC-derived NSPCs from two different developmental stages. On day 8, between DT1_A and DT1_U, 150 genes were differentially expressed with our criteria (|fold change| > 1.5 and false discovery rate <0.05), and pathway analyses showed significant enrichment of those DEGs in “Wnt/β-Catenin Signaling” (Table S10). Among the DEGs in this pathway, inhibitors of the signaling pathway [39–41] were upregulated, and a Wnt receptor and its downstream genes were downregulated in DT1_A-derived NSPCs (Fig. S7A), implying diminished Wnt signaling activity during early neurodevelopment in a psychotic patient. We investigated the proliferation and viability of NSPCs at this time point and found no differences between the twins (Fig. S7B, C). On day 24, we found no DEGs meeting the criteria between the twins. However, when we investigated the expression pattern of genes regulating GABAergic neuron specification, key transcription factors DLX1 and DLX2 [42] were significantly upregulated in DT1_A-derived NPCs compared with those in DT1_U-derived cells, which was confirmed by RT-qPCR (Fig. S7D, E). In contrast, there was no difference in the expression of PAX6 and NEUROG2, genes regulating the generation of cortical excitatory neurons [43], between the twins (Fig. S7F, G). The expression of neither DLX1 nor DLX2 differed between the twins on day 8 (data not shown). Furthermore, the most genes included in the “GABA Receptor Signaling” pathway on the scRNA-seq analysis of the organoids already showed significant
upregulation in 24-day-old NPCs from DT1_A (Fig. S7H). In addition, activation of Wnt/β-catenin signaling during early neurodevelopment by treatment with LiCl or Wnt3a tended to suppress the expression of GABAergic specification-associated genes specifically in DT1_A-derived NSPCs (Fig. S7D, E and H). Thus, in the affected
twin, Wnt signaling activity was diminished during the very early developmental stage and caused the unbalanced differentiation of GABAergic neurons in cortical development.

We then evaluated the proliferation of forebrain NPCs on day 30. Although there was no difference between the twins on day 8 (Fig. S7C), consistent with the findings from cerebral organoids (Figs. 1e, f and 2a, b), DT1_A-derived NPCs were remarkably less proliferative than those derived from DT1_U at this later stage. LiCl had no obvious effect on DT1_U NPCs, whereas it significantly improved cell proliferation in DT1_A NPCs (Figs. 3b, c and S7I, J), confirming that decreased Wnt signaling activity affected the proliferation of neuronal cells during cortical development in DT1_A. We confirmed the iPSC’s clonal variation effect on NPC proliferation was smaller than the effects of disease status or LiCl treatment (Fig. S7J and Table S6).

Affected twin-derived neuronal networks exhibit altered excitatory/inhibitory balance at later neurodevelopmental stage

To examine the consequences of the upregulation of genes regulating GABAergic neuron differentiation observed in DT1_A-derived NPCs during early developmental stages, we further differentiated the cells into mature cortical neurons exhibiting spontaneous firing (Fig. S8A). Whereas soma size and neuronal dendritic arborization did not differ between 120-day-old neurons from the twins (data not shown), DT1_A neurons exhibited more dendritic protrusions than DT1_U neurons (Fig. S8B), suggesting an accelerated maturation of the patient’s neurons. We then investigated the balance of neuronal subtypes among iPSC-derived cortical networks by electrophysiological and immunocytochemical analyses on day 120. The neurons of the twins did not show any notable differences in the frequency or amplitude of excitatory or inhibitory synaptic currents (Fig. S8C–H). However, immunolabeling neurons with the presynaptic marker synapsin-1 (SYN1) and the postsynaptic markers Homer1 (for excitatory synapses) or Gephyrin (for inhibitory synapses) revealed an imbalance of excitatory and inhibitory synaptic density between the twins. DT1_A neurons exhibited a marked decrease in the density of SYN1+Homer1+ excitatory synapses (Figs. 3d, e and S8I, J). Conversely, there was a significant increase in SYN1+Gephyrin+ inhibitory puncta in DT1_A compared with DT1_U-derived neurons (Figs. 3f, g and S8K, L). Moreover, the proportion of GABAergic neurons was markedly higher in DT1_A than in DT1_U (Figs. 3h, i and S8M, N). Activation of Wnt signaling by LiCl treatment during the early stage (days 4–24) exerted no obvious effects on the density of excitatory synapses in either twin (Figs. 3e and S8I). However, specifically in DT1_A neurons, LiCl significantly reduced the density of inhibitory synapses and the GABAergic population (Figs. 3g–i and S8K, M). Importantly, cortical neurons derived from iPSCs of healthy control individuals (Figs. S1A and S8O) behaved indistinguishably from DT1_U neurons, whereas they exhibited significant differences in both synaptic densities and GABAergic proportion from DT1_A neurons (Figs. 3e, g, i and S8I, K, M). This finding suggests that the increased GABAergic specification phenotype is indeed associated with psychosis. Thus, diminished Wnt/β-catenin signaling during the early stages of neurodevelopment leads to a neurodevelopmental shift toward increased inhibition in the excitation and inhibition (E/I) balance of in vitro networks formed from DT1_A-derived cortical neurons at the later stage. We confirmed the effect of variability among each iPSC clone on these phenotypes was smaller than the effects of disease status or LiCl treatment (Fig. S8J, L, N and Table S6).

iPSC-derived NPCs from three monozygotic twins with psychoses show upregulation of GABAergic synapse-related genes compared with their healthy co-twins

Taken together, these findings suggest that abnormally enhanced GABAergic specification during cortical development is one of the cellular endophenotypes of psychosis. To further evaluate the relevance of this phenotype to the disorder, we analyzed two additional pairs of monozygotic twins discordant for SZ (Figs. 4a, b and S1A). iPSCs were established from LCLs of each individual (Fig. S9A, B) and differentiated into forebrain NPCs (Fig. 3a). We then performed bulk RNA-seq and compared the expression patterns of genes annotated with at least one of the terms “GABAergic Synapse” in KEGG pathway (hsa04727) or Gene Ontology (GO: 0098982) and “GABA Receptor
Signaling in IPA among three patients with psychoses and their healthy co-twins (DT1, DT2, and DT3) on day 24. Among 146 genes analyzed, 37 genes were significantly differentially expressed between the affected twins and the unaffected twins (Table S11). Compared with the NPCs from the unaffected twins, the NPCs from all three twins affected by psychoses exhibited upregulation of 35 genes, including genes encoding both pre- and postsynaptic GABA receptor subunit and ion channels (Fig. 4c), and downregulation of only two genes (Fig. S9C and Table S11). Thus, there was a significant upregulation of genes associated with GABAergic synapses during early neurodevelopment between the twins affected with psychoses and their co-twins ($p < 1.0244e-08$, Fisher’s exact test).

**Discussion**

Although decades of research have suggested several neurodevelopmental mechanisms underlying SZ and BD,
substantial genetic heterogeneity among individuals has hampered the identification of specific disease-associated cellular phenotypes and their temporal order in the pathogenesis of these disorders, especially in sporadic cases that represent the vast majority of the patients. Therefore, analyzing patient neurons by simulating brain development with a well-controlled genetic background has been required.

In this study, with cerebral organoids and forebrain NPCs derived from iPSCs of monozygotic twins discordant for psychoses, we propose the disease-associated staged dysregulation of neuronal development in which deficits in Wnt signaling pathway precede the reduced proliferation and marked dorsal-ventral fate shift to neuronal network E/I balance tilted toward GABAergic interneuron differentiation. Previous studies have reported the alterations in neuronal fate specification toward increased ventralization/GABAergic differentiation in iPSC-derived neuronal cells from the patients with BD [44, 45]. Chen et al. [44] demonstrated the enhanced ventralization during early neurodevelopment of the patient-derived cells, while the neurons of healthy individuals were more shifted to the dorsal fate. They also showed that LiCl can promote dorsalization of the patients’ neurons. This finding was confirmed by Kim et al. [45] in which patient-derived neurons exhibited higher expression of GAD1 and increased GABAergic specification compared with healthy individuals. Even though these studies including ours utilized different neuronal differentiation protocols and analyzed completely independent patient cohorts, each study observed the similar phenotype of enhanced GABAergic specification in iPSC-derived neurons form patients with BD, implying that the alterations in neuronal fate specification is one of the mechanisms underlying the disorder. In 24-day-old NPCs derived from DT1_A, gene cohorts important for the differentiation of GABAergic interneurons were upregulated (Fig. S7D, E, H) in accordance with our functional studies indicating increased numbers of GABAergic neurons and inhibitory synapses in neural networks in vitro (Figs. 2d and 3g, i). During early neural development, Shh and Wnts act antagonistically in the dorsal-ventral patterning of the neural tube [46]. Interestingly, our RNA-seq analyses of iPSC-derived NSPCs identified that SHH tended to be upregulated in DT1_A on day 8 (log2FC = −0.77339, Padj = 0.07), in addition to diminished Wnt signaling (Fig. S7A). These alterations suggest that dysregulated Wnt/β-catenin signaling enhanced the ventralization of the affected twin’s neuronal cells via Shh signaling.

In the present study, while DT1_A-derived neurons exhibited significant increase in the inhibitory synaptic puncta and marked decrease in the excitatory puncta compared with DT1_U neurons (Fig. 3e, g), they did not show any obvious electrophysiological abnormalities except for the significant reduction of mIPSC amplitude by LiCl in DT1_A-derived neurons (Fig. S8D, E, G, H). One possible mechanism underlying this contradiction is the functional maturity of iPSC-derived neurons. Since protein and gene expression might precede electrophysiological properties by days or even weeks, it is possible that iPSC-derived neurons in our study is not functionally fully matured even they expressed synaptic markers. Indeed, DT1_A neurons had remarkably more Gephyrin puncta than DT1_U (Fig. S10A) suggesting an increased GABAergic release on dendrites in DT1_A-derived neuronal networks [47] which supports our finding of the increase in GABAergic population in DT1_A neurons. On the other hand, consistent with our findings on the mIPSC amplitude, the size of Gephyrin puncta did not differ between the twins (Fig. S10B), suggesting that there is no obvious difference between the twins in the functional/electrophysiological maturity of synapses on iPSC-derived neurons. LiCl significantly decreased both the density and size of Gephyrin puncta especially in DT1_A neurons (Fig. S10A, B). The significant attenuation of mIPSC amplitude in LiCl-treated DT1_A neurons might reflect both reduction and immaturity of the inhibitory synapses by LiCl.

Previous studies analyzing iPSC-derived neurons from the patients with SZ have suggested the alterations in synaptic function such as attenuation of neuronal connectivity [48], reduced neuronal activity [49–51], deficit in synaptic density [48, 49, 51–53], and neurotransmitter release [49, 52, 54]. However, these findings relied on the analyses of spontaneous synaptic events and morphology. Although spontaneous events are insufficient predictor of synaptic maturity and function, there are few reports tested evoked synaptic transmission with neurons classically (i.e., not transcription factor-based) differentiated from human PSCs, suggesting the limitation of studying mature neuronal properties, such as synaptic transmission, with those PSC-derived neurons. Classically differentiated PSC-derived neurons as analyzed in the present study have heterogeneity of maturation states [55] and it might cause the difficulty in investigating synaptic transmission. On the other hand, transcription factor-based induced neuronal cells (iNs) are reported to exhibit higher degree of synaptic maturation than classical PSC-derived neurons and evoked EPSC and IPSC [56, 57]. To date, by analyzing the evoked synaptic events, several studies have demonstrated failures in neurotransmitter release in iNs from PSCs carrying disease-associated gene mutation such as STXBP1 which causes infantile early epileptic encephalopathy [58] and NRXN1 associated with autism and SZ [59]. Moreover, recent studies developed an autaptic culture system for human iPSC-derived neurons for the analysis of evoked synaptic transmission and short-term plasticity [60, 61].
Thus, further investigation of the evoked synaptic events on twins’ iPSC-derived neurons with those alternative system might support or strengthen our findings of the altered E/I balance of in vitro networks in DT1_A neurons.

Several studies of postmortem brains from patients with SZ, schizoaffective disorder, and/or BD have demonstrated a preferential decrease in the number of interneurons in both the cerebral cortex and hippocampus, suggesting that these disorders are associated with disruptions in GABAnergic networks [62]. Our analysis of postmortem brain tissues from patients with psychoses and non-psychiatric control individuals (Fig. S11A) [35] also demonstrated significant downregulation of GABAergic synapse-related genes in the patient brains. Among the 146 genes investigated, 107 genes exhibited decreased expression, and only 11 genes were upregulated in the psychotic brains (p < 6.4038e-21, Fisher’s exact test) (Fig. S11B and Table S11). The enhanced GABAergic specification observed in iPSC-derived neuronal cells from the patient with psychoses (Figs. 4c and S9C) is seemingly inconsistent with those findings. However, postmortem brain data are an end stage of the disease and reflect consequences of a life-long illness and pharmacological intervention. Thus, the specific perturbations during early brain development that underlie the reduction in GABAergic neurons in adults remain unclear. Human iPSC-derived neuronal cells recapitulate cells of the fetal brain [27, 63]; therefore, iPSC-based models of neuronal disorders provide us an opportunity to investigate molecular and cellular alterations before disease onset. Moreover, the pathological processes likely differ between the early developmental stage and adulthood. For example, in autism, brain overgrowth has been reported in early development, but this is followed by premature arrest of growth, resulting in smaller brain volume in adults [64]. Thus, an excess of GABAergic neurons during early development may be followed by marked decreases in the GABAergic neuronal population in adults after disease onset. Furthermore, diminished Wnt signaling activity during the very early neurodevelopmental stage might affect the brain volume of DT1_A before the onset. Studies of individuals at high risk for SZ consistently showed that cerebral cortex gray matter volume is smaller in this population compared with controls [65], suggesting that brain volume is already small at the onset of illness, and further reduction of gray matter volume occurs after the onset. However, the prodromal studies of SZ also suggested that brain shrinkage mainly takes place in the first 1.5 years after the onset [66]. Thus, the correlation between the cellular phenotype and the changes in morphology of patient’s brain remains controversial.

Studies using iPSC-derived neuronal cells from patients with SZ or BD have reported changes in Wnt signaling pathways [45, 48, 67, 68] altered neural fate specification [44, 45], mitochondrial abnormalities [69], dysregulated neuronal activity [49–51] and excitability [69, 70], and synaptic dysfunctions [48, 49, 51–54]. A recent study using cerebral organoids also showed altered excitability of BD patients-derived neurons [71]. However, the relationships among the alterations and their order have not been well investigated. Our scRNA-seq analysis of cerebral organoids and additional functional genomic analyses with time-point profiling of iPSC-derived neuronal cells enabled concluding that pathogenic decreases in cell proliferation and enhanced GABAergic specification temporally follow defective Wnt/β-catenin signaling pathway in iPSC-derived neuronal cells from a patient with SA-B. Premature commitment to neuronal differentiation resulting from reduced progenitor proliferation and excess network inhibition during cortical development may cause an E/I imbalance in later adult neuronal network function.

In the current study, the fundamental cause of discordance in the cellular phenotypes between the twins remain unclear. To identify a genomic discordance between DT1_A and DT1_U, we performed whole genome sequencing analysis of peripheral blood samples and have not identified any obvious genomic differences, such as single nucleotide variants, insertions and deletions, and long interspersed element-1 (LINE-1) insertion. On the other hand, based on DNA methylation analyses, we identified a CpG site which were differentially methylated throughout blood to iPSC-derived NPCs between the twins. It might suggest a contribution of epigenetic differences which are maintained throughout the reprogramming process to the discordance in cellular phenotypes in DT_1 pair. Further investigations including whole genome DNA methylation analysis might resolve this complexity.

Based on a strategy to minimize genetic variability by analyzing monozygotic twin pairs discordant for the disorders, the current study proposes that a shift in the balance of neuronal and synaptic prevalence toward GABAergic specification during early cortical development is one of the endophenotypes of psychoses. Further studies to clarify the correlation between the cellular phenotype and the patient’s symptoms is an essential issue to be addressed for understanding of the disease pathogenesis and discovering novel therapeutic targets. Moreover, future studies utilizing the methodology used in this study will focus on reconstituting the entire disease cascade for psychoses, while the parallel accumulation of data from iPSC lines of other patients may lead to an understanding of the general principles underlying complex, variegated psychiatric disorders.

**Data availability**

All datasets generated during the current study are available from the Lead Contact upon reasonable request. Single-cell
RNA sequencing data that support the findings of this study have been deposited at the Gene Expression Omnibus (GEO) under accession number GSE120190.

Code availability

All codes generated during the current study are available from the Lead Contact upon reasonable request.

Acknowledgements

We thank the Support Unit for Bio-Material Analysis at RIKEN CBS, with special thanks to K. Ohtawa, F. Sakai, and K. Fukumoto. We also thank N. Kume, Y. Hisano, and M. Kur- osawa (RIKEN CBS) for technical support; A. Matsushima and M. Ishii (RIKEN BDR) for assistance with the infrastructure for the data analysis; H. Danno (Knowledge Palette, Inc.) for the development of data analysis software for single-cell transcriptomes; I. Asaka and members of his lab (CIRA, Kyoto Univ.) for practical training on the generation and maintenance of human iPSCs; T. Hayashi (RIKEN BDR), M. Toyoshima, T. Yoshikawa (RIKEN CBS), and H. Okano (Keio Univ.) for discussion; Y. Kageyama (RIKEN CBS), S. Nanko (Teikyo University), and Y. Okazaki (Nagasaki University) for clinical assessment; and C. Yokoyama (RIKEN CBS) for manuscript editing. We thank all the participants of the study. This work was supported by the JSPS Grant-in-Aid for Young Scientists (B) (15K19753 and 17K160407) to TS; funds from RIKEN BSI to YG; JST CREST JSPS Grant-in-Aid for Young Scientists (Start-up) (25891032) and the JSPS Grant-in-Aid for Young Scientists (B) (17K160405208H0002) and MEXT/JSPS Grants-in-Aid for Scientific Research (KAKENHI) (18H05435, 18H05428, and 17H01573) to TK.

Author contributions

TS and TK designed and conducted the study and wrote the paper, TS, TEC, YS, NF-T, and KT performed the experiments. TS, YS, MY, NF-T, KJMB, and IN analyzed the data. ACMP, JAE, and YG supervised the analyses. TK performed the clinical assessment.

Compliance with ethical standards

Conflict of interest

We have no conflicts of interest to disclose except for a grant from Takeda Pharmaceutical to TK outside of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Jäkel S, Aguirre E, Mendanha Falcão A, van Bruggen D, Lee KW, Knuesel I, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019;566:543–7.
2. Krishnaswami SR, Grindberg RV, Novotny M, Venevalpy P, Lacar B, Bhutani K, et al. Using single nuclei for RNA-seq to capture the transcriptome of postmortem neurons. Nat Protoc. 2016;11:499–524.
3. Lake BB, Ai R, Kaeser GE, Salatthia NS, Yung YC, Liu R, et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016;352:1586–90.
4. Bershteyn M, Nowakowski TJ, Pollen AA, Di Lulio E, Nene A, Wyawah-Boris A, et al. Human iPSC-derived cerebral organoids model cellular features of lissencephaly and reveal prolonged mitosis of outer radial glia. Cell Stem Cell. 2017;20:435–49.
5. Ietemova V, Manikakis G, Kreeft O, Jabali A, Weynans K, Wilkens R, et al. An organoid-based model of cortical development identifies non-cell-autonomous defects in Wnt signaling contributing to Miller-Dieker syndrome. Cell Rep. 2017;19:50–9.
6. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373–9.
7. Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L, et al. FOXG1-dependent dysregulation of gaba/glutamate neuron differentiation in autism spectrum disorders. Cell. 2015;162:375–90.
8. Liu YN, Lu SY, Yao J. Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia. Psychiatry Clin Neurosci. 2017;71:579–99.
9. Nakazawa T, Kikuchi M, Ishikawa M, Yamamori H, Nagayasu K, Matsumoto T, et al. Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPSCs from monzygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine. Schizopr Res. 2017;181:75–82.
10. Sasagawa Y, Danno H, Takada H, Ebisawa M, Tanaka K, Hayashi T, et al. Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads. Genome Biol. 2018;19:29.
11. Mereu E, Lafzi A, Moutinho C, Ziegenhain C, MacCarthy DJ, Álvarez-Varela A, et al. Benchmarking single-cell RNA sequencing protocols for cell atlas projects. Nat Biotechnol. 2020. https://doi.org/10.1038/s41587-020-0469-4.
12. Ono S, Imamura A, Tanaka S, Kurotaki N, Ozawa H, Yoshiura K, et al. Failure to confirm CNVs as of aetiological significance in twins discordant for schizophrenia. Twin Res Hum Genet. 2010;13:455–60.
13. Kukiuchi C, Ishiwata M, Nanko S, Oraki N, Iwata N, Umekage T, et al. Up-regulation of ADM and SEPX1 in the lymphoblastoid cells of patients in monzygotic twins discordant for schizophrenia. Am J Med Genet. 2008;147:557–64.
14. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.
17. Zultfigar S, Fritz B, Nieweg K. Episomal plasmid-based generation of an iPSC line from an 83-year-old individual carrying the APOE4/4 genotype: i11001. Stem Cell Res. 2016;17:544–6.
18. Ohnuki M, Takahashi K, Yamanaka S. Generation and characterization of human induced pluripotent stem cells. Current protocols in stem cell biology. 2009:9-A2.1–4-A2.25.
19. Koyanagi-Aoi M, Ohnuki M, Takahashi K, Okita K, Noma H, Sawamura Y, et al. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. Proc Natl Acad Sci USA. 2013;110:20569–74.
20. Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc. 2014;9:2329–40.
21. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5.
22. Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202–14.
23. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
24. Giner G, Smyth GK. statmod: probability calculations for the inverse Gaussian distribution. R J. 2016;8:339–51.
25. van der Maaten LJP, Hinton GE. Visualizing high-dimensional data using t-SNE. J Mach Learn Res. 2008;9:2579–605.
26. Birey F, Andersen J, Makinson CD, Islam S, Wei W, Huber N, et al. Assembly of functionally integrated human forebrain spheroids. Nature. 2017;545:54–9.
27. Camp JG, Badsha F, Florio M, Kanton S, Gerber T, Wilsch-Bräuning H, et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc Natl Acad Sci USA. 2015;112:15672–7.
28. Pollen AA, Nowakowski TJ, Chen J, Retalack H, Sandoval-Expinosa C, Nicholas CR, et al. Molecular identity of human outer radial glia during cortical development. Cell. 2015;163:55–67.
29. Quadrato G, Nguyen T, Macosko E, Sherwood JL, Yang SM, Berger DR, et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature. 2017;545:48–53.
30. Zhou X, Lindsay H, Robinson MD. Robustly detecting differential expression in RNA sequencing data using observation weights. Nucleic Acids Res. 2014;42:e91.
31. Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag; 2016.
32. Kondo T, Funayama M, Tsukita K, Osaka H, Goto K, et al. Modeling Alexander disease with patient iPSCs reveals cellular and molecular pathology of astrocytes. Acta Neuropathol Commun. 2016;4:69.
33. Kim D, Langmead B, Salzberg SL. HISAT: an efficient and sensitive aligner with low memory requirements. Nat Methods. 2015;11:357–60.
34. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.
35. Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L, et al. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat Neurosci. 2018;21:1117–25.
36. Collado-Torres L, Burke EE, Peterson A, Shin J, Straub RE, Rajagopalan A, et al. Regional heterogeneity in gene expression, regulation, and coherence in the frontal cortex and hippocampus across development and schizophrenia. Neuron. 2019;103:203–16.
37. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525–7.
38. RStudio Team RStudio: Integrated Development for R. RStudio, PBC, Boston, MA, 2020. http://www.rstudio.com/.
39. Cadigan KM, Waterman ML. TCP/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol. 2012;4. https://doi.org/10.1101/cshperspect.a007906.
40. Leow SC, Poschmann J, Too PG, Yin J, Joseph R, McFarlane C, et al. The transcription factor SOX6 contributes to the developmental origins of obesity by promoting adipogenesis. Development. 2016;143:950–61.
41. Bardy C, van den Hurk M, Kakaradov B, Erwin JA, Jaeger BN, Hernandez RV, et al. Predicting the functional states of human iPSC-derived neurons with single-cell RNA-seq and transcriptome modeling. Mol Psychiatry. 2018;23:271–81.
42. Zhang Y, Pak C, Han Y, Ahenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785–98.
43. Yang N, Chanda S, Marro S, Ngh YH, Janas JA, Haag D, et al. Generation of pure GABAergic neurons by transcription factor programming. Nat Methods. 2017;14:621–30.
44. Patrze C, Han Y, Covy J, Yi F, Maxeiner S, Wernig M, et al. Analysis of conditional heterozygous STXBP1 mutations in human neurons. J Clin Invest. 2015;125:3560–71.
59. Pak C, Danko T, Zhang Y, Aoto J, Anderson G, Maxeiner S, et al. Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1. Cell Stem Cell. 2015;17:316–28.

60. Meijer M, Rehbach K, Brunner JW, Classen JA, Lammertse HCA, van Linge LA, et al. A single-cell model for synaptic transmission and plasticity in human iPSC-derived neurons. Cell Rep. 2019;27:2199–211.

61. Rhee HJ, Shaib AH, Rehbach K, Lee C, Seif P, Thomas C, et al. An autaptic culture system for standardized analyses of iPSC-derived human neurons. Cell Rep. 2019;27:2212–28.

62. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 2001;25:1–27.

63. Brennand K, Savas JN, Kim Y, Tran N, Simone A, Hashimoto-Torii K, et al. Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia. Mol Psychiatry. 2015;20:361–8.

64. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA. 2003;290:337–44.

65. Brent BK, Theremens HW, Keshavan MS, Seidman LJ. Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings. Child Adolesc Psychiatr Clin N Am. 2013;22:689–714.

66. Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Lee CU, Ciszewski AA, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry. 2003;160:156–64.

67. Madison JM, Zhou F, Nigam A, Hussain A, Barker DD, Nehme R, et al. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. Mol Psychiatry. 2015;20:703–17.

68. Topol A, Zhu S, Tran N, Simone A, Fang G, Brennand KJ. Altered Wnt signaling in human induced pluripotent stem cell neural progenitor cells derived from four schizophrenia patients. Biol Psychiatry. 2015;78:e29–34.

69. Mertens J, Wang QW, Kim Y, Yu DX, Pham S, Yang B, et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015;527:95–9.

70. Stern S, Santos R, Marchetto MC, Mendes APD, Rouleau GA, Biesmans S, et al. Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients’ responsiveness to lithium. Mol Psychiatry. 2018;23:1453–65.

71. Kathuria A, Lopez-Lengowski K, Vater M, McPhie D, Cohen BM, Karmacharya R, et al. Transcriptome analysis and functional characterization of cerebral organoids in bipolar disorder. Genome Med. 2020;12:34.